Mariana Oncology’s Post

Our novel, DLL3-targeted radioligand therapy is designed for potential high, rapid tumor uptake and retention, and fast clearance of unbound molecules. Today at the ESMO - European Society for Medical Oncology Congress 2024, we’re presenting preclinical results that characterize in vitro and in vivo properties of our experimental treatment. (Poster #1153P) #ESMO2024 #RLT #radioligandtherapy #oncology 

Mariana Oncology today announced the company will be acquired by Novartis for up to $1.75B. Together, we will accelerate the development and delivery of precision radioligand therapeutics – therapies with the potential to transform the standard of care for people living with cancer. Read more about the exciting news here: https://lnkd.in/geVhN7RG

Meet the visionary force behind our scientific endeavors, Alonso Ricardo! As our Chief Scientific Officer, he brings cutting-edge expertise and innovation to our research journey.   Alonso has over a decade of drug discovery and development experience leading scientific programs across multiple therapeutic programs including immunology, metabolic diseases, and oncology.   We are glad to have you on #TeamMariana, Alonso. Your commitment is truly appreciated!   Stay tuned for more leadership team spotlights!

Did you know that the choices we make every day can lower our risk for different types of #cancer? Research shows that up to 50% of cancer cases and about 50% of cancer deaths are preventable with the knowledge we have today.   At Mariana, we are not only dedicated to transforming cancer treatment, but the experience of cancer care for people living with this disease, helping to maintain quality of life throughout a person’s cancer journey. Learn more here: www.marianaoncology.com   And join us in celebrating #NationalCancerPreventionMonth by learning more about how to reduce your cancer risk and detect cancer early. Visit https://lnkd.in/gT2vd6hZ